Agile Therapeutics (AGRX) Earning Somewhat Positive News Coverage, Study Shows

Media headlines about Agile Therapeutics (NASDAQ:AGRX) have trended somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Agile Therapeutics earned a daily sentiment score of 0.15 on Accern’s scale. Accern also assigned headlines about the specialty pharmaceutical company an impact score of 44.8654274634958 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Agile Therapeutics (NASDAQ:AGRX) traded up $0.15 during trading hours on Thursday, reaching $3.47. 314,241 shares of the company’s stock traded hands, compared to its average volume of 467,150. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.10 and a quick ratio of 4.10. Agile Therapeutics has a 52-week low of $1.93 and a 52-week high of $5.60. The stock has a market cap of $111.79, a P/E ratio of -3.77 and a beta of 2.00.

Agile Therapeutics (NASDAQ:AGRX) last posted its earnings results on Monday, November 6th. The specialty pharmaceutical company reported ($0.22) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.03. sell-side analysts predict that Agile Therapeutics will post -0.97 EPS for the current year.

AGRX has been the subject of several recent analyst reports. HC Wainwright set a $8.00 price objective on shares of Agile Therapeutics and gave the company a “buy” rating in a research note on Friday, December 22nd. Cantor Fitzgerald reiterated a “buy” rating and issued a $8.00 price objective on shares of Agile Therapeutics in a research note on Monday, November 20th. Royal Bank of Canada reiterated a “buy” rating and issued a $10.00 price objective on shares of Agile Therapeutics in a research note on Wednesday, October 18th. Noble Financial reiterated a “buy” rating on shares of Agile Therapeutics in a research note on Friday, December 22nd. Finally, William Blair cut shares of Agile Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, December 26th. One analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $9.20.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at

About Agile Therapeutics

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Insider Buying and Selling by Quarter for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply